AbbVie will invest 380 million dollars to build two new active pharmaceutical ingredient manufacturing facilities at its North Chicago, Illinois campus to bolster US based production of medicines for neuroscience and obesity. Construction is scheduled to begin in spring 2026, with both plants expected to be fully operational in 2029, underscoring the company’s long horizon approach to expanding small molecule capacity in the United States.
The new facilities will incorporate advanced process technologies and artificial intelligence driven systems intended to increase efficiency, consistency and scalability in API production. AbbVie said the sites will be designed to handle complex synthetic routes and highly sensitive process steps that underpin its pipeline of next generation medicines for chronic neurological conditions and metabolic disease. API manufacturing is regarded as one of the most technically demanding stages of pharmaceutical production, and the decision to add capacity domestically reflects efforts across the sector to reduce dependence on overseas suppliers.
The expansion will create about 300 new jobs in North Chicago, including positions for engineers, scientists, manufacturing operators and laboratory technicians. State officials have framed the project as a vote of confidence in Illinois as a life sciences hub, highlighting the region’s skilled workforce, infrastructure and research ecosystem. For the local community, the investment brings a mix of high skilled employment opportunities and secondary economic activity tied to the construction and long term operation of the plants.
AbbVie has positioned this 380 million dollar outlay as part of a much larger commitment to US based research, development and capital spending over the coming decade. The company has pledged around 100 billion dollars in US R&D and capital investments over ten years, which includes an earlier 195 million dollar project at the same North Chicago site to expand API output for immunology, oncology and neuroscience therapies. Together, these projects signal a strategic emphasis on securing domestic supply chains for key therapeutics and supporting late stage pipeline launches with in house manufacturing depth.
Industry analysts note that AbbVie’s move comes amid policy pressure to reshore critical drug manufacturing capacity and a shifting cost calculus following tariffs on imported branded medicines. By committing to new US facilities that will not come online until the end of the decade, AbbVie is effectively betting that supply security, regulatory predictability and proximity to core R&D operations will outweigh near term cost advantages offered by some offshore locations. For patients, the long term impact is expected to be greater resilience in the supply of high value therapies that target complex chronic conditions, although pricing and access will continue to be shaped by broader market forces and policy decisions.
